ew treatment criteria for chronic hepatitis B without considering alanine aminotransferase levels to prevent hepatocellular carcinoma

Asan Medical Center0 个研究点目标入组 15,000 人开始时间: 待定最近更新: 2022年1月11日

试验速览

暂无简介。

•1.Untreated CHB Patient Cohort
•1) Adult male or female patients over 20 years of age.
•2) Having serum hepatitis B surface antigens for >6 months
•3) Never having any evidence of liver cirrhosis, radiologically, clinically, or both.
•4) Serum ALT levels at baseline <2× upper limit of normal (ULN) [ULN of ALT =40 U/L]
•5) Never having received HBV treatment, including nucleos(t)ide analogues.
•2.Treated CHB Patient Cohort
•1) Adult male or female patients over 20 years of age.
•2) Having serum hepatitis B surface antigens for >6 months.
•3) Never having any evidence of liver cirrhosis, radiologically, clinically, or both.
•4) Having started HBV treatment with entecavir or tenofovir.

•1. Untreated CHB Patient Cohort
•1) Patients with evidence of HCV infection, HDV infection or HIV infection.
•2) Patients with prior antiviral treatment, malignancy, or immunosuppressive agents.
•3) Insufficient medical records.
•4) Patients with ALT levels at baseline >1× ULN and HBV DNA <2,000 IU/mL.
•5) Patients who have received a liver transplantation or have history or evidence of HCC.
•6) Patients with ALT elevation >2× ULN during the initial 1 year of follow-up.
•7) Patients who were followed up less than a year.
•2.Treated CHB Patient Cohort
•1) Patients with evidence of HCV infection, HDV infection, or HIV infection.
•2) Patients with prior antiviral treatment, malignancy, or immunosuppressive agents.
•3) Insufficient medical records.
•4) Patients who have received a liver transplantation or have history or evidence of HCC.
•5) Patients who were followed up less than a year.

发起方